Shenzhen Geno-immune Medical Institute

This trial tests a new vaccine called LV-SMENP, designed to teach the body's immune cells to recognize and attack the COVID-19 virus. The vaccine uses a harmless virus to deliver pieces of the coronavirus into dendritic cells, which then activate T cells to fight infection. The s…

This Phase 1 trial tests a new type of COVID-19 vaccine made from artificial antigen presenting cells (aAPC). The vaccine is designed to teach the body's T cells to recognize and attack the SARS-CoV-2 virus. The study includes healthy volunteers and people with mild COVID-19, and…

This early-stage trial is testing a personalized vaccine made from a patient's own immune cells (dendritic cells) to treat prostate cancer. The vaccine is designed to teach the immune system to recognize and attack cancer cells by targeting multiple tumor antigens. The study invo…

This early-phase trial is testing whether specially engineered immune cells (OC-CTLs) can safely fight ovarian cancer. Twenty women with advanced-stage disease will receive 2 to 4 infusions of these cells. Researchers will monitor side effects and check if tumors shrink or stabil…

This trial investigates a new type of CAR-T cell therapy for people with B-cell acute lymphoblastic leukemia (B-ALL) whose cancer has stopped responding to anti-CD19 treatment. The therapy uses a patient's own immune cells, modified to target several other markers on leukemia cel…

This study tests whether specially engineered immune cells (EIE) can safely fight cancer. Researchers take a patient's own immune cells, modify them to target tumor-related markers, and infuse them back. The trial involves 100 people with various cancers whose tumors show specifi…

This trial investigates whether specially grown immune cells, called pathogen-specific cytotoxic T lymphocytes (CTLs), can safely and effectively treat stubborn infections like EBV, CMV, and adenovirus in people with weakened immune systems, such as stem cell or organ transplant …

This trial tests a combination of genetically modified immune cells (CAR-T cells) that target CD19 plus another protein on B-cell cancers. The goal is to improve treatment for patients whose cancer has returned or not responded to standard therapy. The study enrolls 100 participa…

This early-phase study tests a new treatment for glioblastoma, an aggressive brain cancer. The approach uses a patient's own immune cells, modified in the lab to better recognize and attack the tumor, combined with chemotherapy. The main goal is to check the safety of this therap…

This trial investigates whether specially engineered immune cells (CAR-T cells) can safely treat advanced or recurrent cervical cancer. The cells are designed to recognize and attack cancer cells that carry certain markers like GD2 or Mesothelin. The study involves 20 adults with…

This early-stage trial tests a new type of immunotherapy called 4SCAR-T cells in 20 people with advanced bladder cancer that has spread and no longer responds to standard treatments. The cells are genetically modified to recognize and attack cancer cells. The study aims to see if…

This study tests a new treatment called 4SCAR19 cells for people with B-cell cancers that have come back or not responded to standard therapy. The treatment uses a patient's own immune cells, modified in a lab to better find and attack cancer cells. The trial aims to check safety…

This study tests a new type of immunotherapy called bi-specific CAR-T cells that target two proteins, CD19 and CD79b, found on B cell cancers. The therapy involves collecting a patient's own immune cells, modifying them to recognize and attack cancer cells, and infusing them back…

This study tests a new treatment called 4SCAR-CD44v6 T cells for people with cancers that have a specific protein called CD44v6. The therapy uses a patient's own immune cells, modified to better recognize and attack cancer cells. The trial will enroll 100 participants to check sa…

This early-phase trial tests a combination of CAR T cells that target three different markers (CLL-1, CD33, and CD123) on leukemia cells in patients with relapsed or refractory acute myeloid leukemia. The study aims to see if this approach is safe and can shrink tumors. Only 10 p…

This trial tests a new treatment for advanced ovarian cancer using a patient's own immune cells, called T cells, that are modified in a lab to better recognize and attack the cancer. About 100 women with stage III or IV ovarian cancer will receive these modified cells. The main g…

This early-stage trial is testing whether specially engineered immune cells (called CAR-T and CTL cells) and a dendritic cell vaccine can safely treat people with neurofibromatosis or schwannomatosis, conditions that cause nerve tumors. The study will enroll 100 participants aged…

This study tests a new treatment using a patient's own immune cells, engineered to recognize and attack cancer cells that have two specific markers (GD2 and CD56). The trial includes 60 people with advanced cancers that have not responded to standard therapy. The goal is to see i…

This study tests a new treatment for people with advanced melanoma that has come back or not responded to standard therapy. The treatment uses specially engineered immune cells (CAR-T cells) that target two proteins, NG2 and DLL3, found on melanoma cells. The goal is to see if th…

This early-phase trial tests a two-part immune therapy for people with T-cell acute lymphoblastic leukemia (T-ALL). First, patients receive specially engineered T cells (CAR-T) that target multiple markers on leukemia cells. Then, they get a booster with cytotoxic T cells and a d…

This trial tests a gene therapy for Fanconi anemia, a rare genetic disorder that causes bone marrow failure and increases cancer risk. Participants receive their own stem cells that have been genetically corrected with a lentiviral vector to fix the faulty FANCA gene. The study e…

This early-stage trial tests a combination therapy for B-cell acute lymphoblastic leukemia (B-ALL). It uses specially engineered immune cells (CAR-T cells and CTLs) followed by a dendritic cell vaccine to target multiple cancer markers. The goal is to achieve a very deep remissio…

This study tests a new treatment called bi-specific CAR-T cells that target two proteins, PSMA and CD70, found on some cancer cells. The therapy involves taking a patient's own immune cells, engineering them to recognize and attack these proteins, and infusing them back. The tria…

This trial tests whether infusing HPV-specific immune cells (HPV-CTLs) can safely reduce or clear HPV infection in people who haven't responded to standard treatments. Up to 100 participants will receive 2 to 4 infusions of these cells. The study measures safety and viral load ch…

This study tests a new treatment for people with advanced or recurrent cervical cancer linked to high-risk HPV. The treatment uses specially engineered immune cells (CC-EIEs) designed to target and attack the cancer. Participants receive several infusions of these cells, and rese…